{"DataElement":{"publicId":"11418056","version":"1","preferredName":"Patient Circulating Tumor-Derived DNA Laboratory Test Result Clinical Trial Eligibility Criteria Tumor Marker Status","preferredDefinition":"An indication of the status of the patient's tumor markers.","longName":"7799614v1.00:11418055v1.00","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"7799614","version":"1","preferredName":"Patient Circulating Tumor-Derived DNA Laboratory Test Result Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The detection of cell-free, neoplasm-derived DNA in patient serum or plasma._The outcome of a laboratory test._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:7799612v1.0","context":"NRG","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7799612","version":"1","preferredName":"Circulating Tumor-Derived DNA Laboratory Test Result Clinical Trial Eligibility Criteria","preferredDefinition":"The detection of cell-free, neoplasm-derived DNA in patient serum or plasma.:The outcome of a laboratory test.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C113243:C36292:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Circulating Tumor-Derived DNA","conceptCode":"C113243","definition":"Neoplasm-derived DNA found in blood plasma and other bodily fluids that is not associated with cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Laboratory Test Result","conceptCode":"C36292","definition":"The outcome of a laboratory test.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CEF19B42-EF3C-5C9C-E053-4EBD850ACF3C","latestVersionIndicator":"Yes","beginDate":"2021-10-22","endDate":null,"createdBy":"BOWSERC","dateCreated":"2021-10-22","modifiedBy":"ONEDATA","dateModified":"2021-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CEF19B42-EF4D-5C9C-E053-4EBD850ACF3C","latestVersionIndicator":"Yes","beginDate":"2021-10-22","endDate":null,"createdBy":"BOWSERC","dateCreated":"2021-10-22","modifiedBy":"BOWSERC","dateModified":"2021-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"11418055","version":"1","preferredName":"Tumor Marker Status","preferredDefinition":"A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations._A condition or state at a particular time.","longName":"11418055v1.00","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"undetectable ctDNA","valueDescription":null,"ValueMeaning":{"publicId":"7801250","version":"1","preferredName":"Circulating Tumor-Derived DNA Negative","longName":"7801250","preferredDefinition":"An indication that circulating tumor-derived DNA has not been detected in a sample.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Circulating Tumor-Derived DNA Negative","conceptCode":"C183129","definition":"An indication that circulating tumor-derived DNA has not been detected in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF807F3C-2487-47C7-E053-4EBD850AEBC0","latestVersionIndicator":"Yes","beginDate":"2021-10-29","endDate":null,"createdBy":"BOWSERC","dateCreated":"2021-10-29","modifiedBy":"ZHWENDY","dateModified":"2023-03-28","changeDescription":null,"administrativeNotes":"10/11/2022: removed alt VM \"undetectable ctDNA\".wz","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAC8A2C8-016D-61EB-E053-731AD00ADADF","beginDate":"2022-10-11","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-10-11","modifiedBy":"ZHWENDY","dateModified":"2022-10-11","deletedIndicator":"No"},{"value":"detectable ctDNA","valueDescription":null,"ValueMeaning":{"publicId":"7801252","version":"1","preferredName":"Circulating Tumor-Derived DNA Positive","longName":"7801252","preferredDefinition":"An indication that circulating tumor-derived DNA has been detected in a sample.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Circulating Tumor-Derived DNA Positive","conceptCode":"C183130","definition":"An indication that circulating tumor-derived DNA has been detected in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF807F3C-24AD-47C7-E053-4EBD850AEBC0","latestVersionIndicator":"Yes","beginDate":"2021-10-29","endDate":null,"createdBy":"BOWSERC","dateCreated":"2021-10-29","modifiedBy":"ZHWENDY","dateModified":"2023-03-28","changeDescription":null,"administrativeNotes":"10/11/2022: removed the alt VM \"detected ctDNA:-wz","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAC8A2C8-016E-61EB-E053-731AD00ADADF","beginDate":"2022-10-11","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-10-11","modifiedBy":"ZHWENDY","dateModified":"2022-10-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7589269","version":"1","preferredName":"Tumor Marker Status","preferredDefinition":"A substance that may be found in tumor tissue or released from a tumor into the blood or other body fluids. A high level of a tumor marker may mean that a certain type of cancer is in the body. Examples of tumor markers include CA 125 (in ovarian cancer), CA 15-3 (in breast cancer), CEA (in ovarian, lung, breast, pancreas, and gastrointestinal tract cancers), and PSA (in prostate cancer).:A condition or state at a particular time.","longName":"C17220:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Marker","conceptCode":"C17220","definition":"A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC991A0F-E319-2624-E053-4EBD850A47F3","latestVersionIndicator":"Yes","beginDate":"2021-03-02","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-03-02","modifiedBy":"ONEDATA","dateModified":"2021-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAC87B97-F387-5DDA-E053-731AD00AF064","latestVersionIndicator":"Yes","beginDate":"2022-10-11","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-10-11","modifiedBy":"ZHWENDY","dateModified":"2022-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Mark status:","url":null,"context":"Alliance"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAC894BB-28BF-6071-E053-731AD00AC286","latestVersionIndicator":"Yes","beginDate":"2022-10-11","endDate":null,"createdBy":"ZHWENDY","dateCreated":"2022-10-11","modifiedBy":"ZHWENDY","dateModified":"2022-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}